Terns Pharmaceuticals Acquired by Merck | Healthcare M&A Deal

Merck has agreed to acquire Terns Pharmaceuticals, a pharmacy business in New Jersey, for $53.00 per share. Terns Pharmaceuticals develops and commercializes pharmaceutical products, supporting Merck’s pharmacy acquisition strategy in healthcare M&A. Merck acquisitions are designed to expand its pipeline and strengthen capabilities tied to pharmacy innovation across NJ. The merger acquisition is structured as a tender offer by a wholly owned subsidiary of Merck, with deal size over $100M and an announced status. As a strategic acquisition, Merck aims to purchase all outstanding shares of Terns Pharmaceuticals in the merger acquisition process, subject to customary tender offer terms and conditions.